Resmed (ASX:RMD) reported Friday fiscal second-quarter earnings of $2.43 per diluted share on a non-GAAP basis, up from $1.88 per diluted share a year earlier.
Analysts polled by Visible Alpha expected $2.32 per diluted share.
Revenue for the three months ended Dec. 31, 2024, rose 10% to $1.28 billion from $1.16 billion a year earlier. Analysts surveyed by Visible Alpha expected $1.27 billion.
The board declared a quarterly cash dividend of $0.53 per share, with a record date of Feb. 13, payable on March 20. This is up from the previously reported period's dividend of $0.48.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。